These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24704106)

  • 21. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
    Duarte DM; Silva-Lima B
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
    Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
    Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 24. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.
    Stefanska AM; Distlerová D; Musaus J; Olski TM; Dunder K; Salmonson T; Mentzer D; Müller-Berghaus J; Hemmings R; Veselý R
    Arch Dis Child; 2017 Oct; 102(10):952-957. PubMed ID: 28554892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The EU's new paediatric medicines legislation: serving children's needs?
    Permanand G; Mossialos E; McKee M
    Arch Dis Child; 2007 Sep; 92(9):808-11. PubMed ID: 17715445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?
    Rose K; Walson PD
    Paediatr Drugs; 2017 Dec; 19(6):515-522. PubMed ID: 28889403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paediatric investigation plans for pain: painfully slow!
    Davies EH; Ollivier CM; Saint Raymond A
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1091-7. PubMed ID: 20821198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Better medicines for children].
    Brasseur D
    Rev Med Brux; 2006; 27 Spec No():Sp25-8. PubMed ID: 21818889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J; Karres J
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Who are the PDCO?
    Dempsey EM; Connolly K
    Eur J Pediatr; 2014 Feb; 173(2):233-5. PubMed ID: 23925423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developing a European framework for research on children's medicines: an examination of the proposed EU regulation on medicinal products for paediatric use.
    Seyberth HW; Demotes-Mainard J; Wrobel P
    Pediatr Nephrol; 2005 Nov; 20(11):1537-40. PubMed ID: 16167134
    [No Abstract]   [Full Text] [Related]  

  • 33. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
    Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.
    Manolis E; Pons G
    Br J Clin Pharmacol; 2009 Oct; 68(4):493-501. PubMed ID: 19843052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reflection on the Pharmaceutical Formulation Challenges Associated with a Paediatric Investigation Plan for an Off-Patent Drug.
    Walsh J
    AAPS PharmSciTech; 2017 Feb; 18(2):250-256. PubMed ID: 27097815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation.
    Lindell-Osuagwu L; Hakkarainen M; Sepponen K; Vainio K; Naaranlahti T; Kokki H
    J Clin Pharm Ther; 2014 Apr; 39(2):144-53. PubMed ID: 24329556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paediatric drug development: the impact of evolving regulations.
    Turner MA; Catapano M; Hirschfeld S; Giaquinto C;
    Adv Drug Deliv Rev; 2014 Jun; 73():2-13. PubMed ID: 24556465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.